Windtree Therapeutics (NASDAQ:WINT) Shares Scheduled to Reverse Split on Monday, April 22nd

Shares of Windtree Therapeutics, Inc. (NASDAQ:WINT) are set to reverse split on Monday, April 22nd. The 1-18 reverse split was announced on Monday, April 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 22nd.

Windtree Therapeutics Trading Down 15.3 %

NASDAQ:WINT traded down $0.06 on Thursday, reaching $0.34. The company’s stock had a trading volume of 1,789,008 shares, compared to its average volume of 280,849. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 2.00. The firm has a market cap of $1.75 million, a price-to-earnings ratio of -0.04 and a beta of 0.61. Windtree Therapeutics has a 12-month low of $0.27 and a 12-month high of $7.79. The stock has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.67.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “neutral” rating on shares of Windtree Therapeutics in a report on Wednesday, January 3rd.

Institutional Investors Weigh In On Windtree Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of WINT. Citadel Advisors LLC purchased a new stake in shares of Windtree Therapeutics in the 4th quarter valued at $27,000. Virtu Financial LLC acquired a new position in Windtree Therapeutics during the 4th quarter worth $28,000. Envestnet Asset Management Inc. grew its stake in Windtree Therapeutics by 894.7% during the 3rd quarter. Envestnet Asset Management Inc. now owns 107,302 shares of the company’s stock worth $32,000 after purchasing an additional 96,515 shares in the last quarter. Millennium Management LLC grew its stake in Windtree Therapeutics by 411.1% during the 2nd quarter. Millennium Management LLC now owns 79,858 shares of the company’s stock worth $33,000 after purchasing an additional 64,232 shares in the last quarter. Finally, Vanguard Group Inc. acquired a new position in Windtree Therapeutics during the 3rd quarter worth $40,000. Hedge funds and other institutional investors own 29.33% of the company’s stock.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.